Nephrogenic systemic fibrosis in Japan: advisability of keeping the administered dose as low as possible.
Tsushima
Yoshito
Y
Takahashi-Taketomi
Ayako
A
Endo
Keigo
K
D003287:Contrast Media / Q000009:adverse effects*; D005355:Fibrosis / Q000139:chemically induced* / Q000453:epidemiology; D005682:Gadolinium; D019786:Gadolinium DTPA / Q000009:adverse effects*; D006571:Heterocyclic Compounds / Q000009:adverse effects*; D006801:Humans; D008279:Magnetic Resonance Imaging; D008536:Meglumine / Q000009:adverse effects / Q000031:analogs & derivatives*; D009942:Organometallic Compounds / Q000009:adverse effects*; D051437:Renal Insufficiency / Q000150:complications*; D012306:Risk; D012307:Risk Factors
D003287:Contrast Media; D006571:Heterocyclic Compounds; D009942:Organometallic Compounds; C062402:gadoteridol; C064572:gadobenic acid; D008536:Meglumine; C064925:gadodiamide; D005682:Gadolinium; D019786:Gadolinium DTPA; C112666:gadoversetamide